BiotechTube

Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

May 3, 2022 → Dec 6, 2027

NCT ID
NCT05280548

About Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat

Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat is a phase 3 stage product being developed by Sanofi for Fabry Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05280548. Target conditions include Fabry Disease.

What happened to similar drugs?

9 of 20 similar drugs in Fabry Disease were approved

Approved (9) Terminated (4) Active (10)
✅agalsidase betaSanofiApproved
✅Fabrazyme (agalsidase beta)SanofiApproved
✅agalsidase betaSanofiApproved
✅AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved
✅Agalsidase betaSanofiApproved
✅agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved
✅Agalsidase betaSanofiApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05280548Phase 3Active

Competing Products

20 competing products in Fabry Disease

See all competitors
ProductCompanyStageHype Score
LucerastatIdorsiaPhase 3
38
Fabrazyme (agalsidase beta)SanofiPhase 2
35
Venglustat (GZ402671) + PlaceboSanofiPhase 3
44
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)SanofiPhase 2
27
agalsidase betaSanofiApproved
35
TropicamideSanofiPre-clinical
26
Fabrazyme (agalsidase beta)SanofiApproved
35
agalsidase betaSanofiApproved
43
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved
43
Gabapentin + placeboSanofiPhase 2
27
Agalsidase betaSanofiApproved
43
GZ/SAR402671SanofiPhase 2
35
agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved
35
Fabrazyme (agalsidase beta)SanofiPhase 3
40
IohexolSanofiPhase 1
21
GZ/SAR402671SanofiPhase 2
35
Fabrazyme (agalsidase beta)SanofiPhase 2
35
Agalsidase betaSanofiApproved
43
Fabrazyme (agalsidase beta) + PlaceboSanofiApproved
43
Agalsidase beta + Agalsidase betaSanofiPhase 3
40